



ASX and Media Release

Viralytics to Present Final Clinical Data from CALM trial at American Society for Clinical Oncology Annual Meeting 2015

13 May 2015, Sydney, Australia: [Viralytics Limited](#) (ASX: VLA, OTC: VRACY) today announced that an Abstract has been accepted for presentation at the [American Society of Clinical Oncology \(ASCO\) Annual Meeting 2015](#), May 29 to June 2, in Chicago, Illinois. The Abstract will be made available on the Meeting website tomorrow morning Australian time and the full poster will be available from the date of the presentation, details below.

The poster presentation will provide the final clinical data from the 57 patient Phase 2 CALM clinical trial of Viralytics' lead drug candidate, [CAVATAK™](#). CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

Poster Presentation

- ***Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma (Abstract #9030)***
- Presenter: Dr Robert Andtbacka MD, CM, Associate Professor at the University of Utah-based Huntsman Cancer Institute and Lead Study Investigator for the CALM trial
- Poster Session: Melanoma/Skin Cancers
- Monday, June 1, 2015, 1:15 PM - 4:45 PM
- Location: S Hall A, Poster Board: #273

The poster abstract will be available on the ASCO website at 5pm Eastern US time on May 13 (7am Sydney time on May 14) - <http://abstracts.asco.org/>. It can also be located from the Viralytics website.

The full poster presentation will be available from Monday June 1, 2015 US time. A link will be provided on the Viralytics website.



About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333